Stephen A. Smith has stirred a renewed debate about cannabis and competitive sport after telling a podcast audience he believes marijuana can act as a performance aid and therefore should be banned from professional competition. His comments arrive amid ongoing conversations about drug testing, player conduct and changing public attitudes toward cannabis.
On a recent episode of The Culture Table Podcast, Smith stated plainly: “I consider weed a performance-enhancing drug.” He argued that substances that can steady a player’s hands or calm anxiety under pressure alter more than raw athleticism—they affect a competitor’s poise and ability to perform in tense moments.
Smith framed his position around the psychological edge he says cannabis can provide: reducing fidgetiness, steadying nerves and allowing athletes to “be immune to the pressure,” in his words. That line of reasoning treats marijuana not just as a lifestyle choice but as something that could change outcomes in close contests.
US ends Hong Kong emergency powers, eases targeted sanctions: Trump-era order remains
OnlyFans scam siphons creators’ earnings: users say accounts were hijacked
For years Smith has been a prominent voice in sports media warning athletes about marijuana use—his critiques went viral as players such as Josh Gordon, D’Angelo Russell, Martavis Bryant and Aldon Smith faced disciplinary and financial consequences for violating league rules. His latest remarks shift the emphasis from moralizing to a policy-centered argument: if a substance improves performance under stress, should it be regulated like other performance enhancers?
- Policy implications: Leagues would need clearer definitions of what counts as a performance-enhancing substance and potentially revise testing protocols and penalties.
- Competitive fairness: Teams and players could argue over whether access to or tolerance for cannabis use creates an uneven playing field in pressure situations.
- Legal and medical complexity: Many jurisdictions have relaxed cannabis laws and medical uses are widely recognized, complicating how sports bodies classify the drug.
- Player welfare and privacy: Any stricter approach raises questions about athletes’ rights, the medical legitimacy of cannabis for pain or anxiety, and where regulation should draw the line.
Smith’s remarks are likely to rekindle a broader discussion rather than settle it. Medical researchers, league officials and athletes themselves remain divided on how cannabis affects performance, and scientific findings do not map neatly onto the rules that govern professional sport.
Ultimately, the debate touches on several intersecting issues: evolving public policy on cannabis, the integrity of competition, and how sports institutions balance health, fairness and enforcement. Whether Smith’s argument shifts any league policies will depend on evidence, stakeholder pressure and the legal landscape—factors that continue to change rapidly.
